Around one in 5,000 babies are born worldwide with a malformation of the outer ear, a condition known as microtia. It can cause severe emotional and psychosocial distress for children, if thereâ€™s no intervention.
Accelerating Australia is well into its next phase of the project, which gives entrepreneurs, business professionals and start-ups the skills they need to translate and commercialise their biomedical ideas.
Vaccines are one of the fastest growing sectors in the pharmaceutical and biotechnology industry. Vaccine technology developer Vaxine, in a project with partners Mylexa and the Australian Respiratory and Sleep Medicine Institute (ARASMI), is bringing together a community of researchers, developers and industries to drive growth of Australian vaccine development.
The AusBiotech Sector Snapshot (October 2017) revealed that there are currently over 130 ASX-listed life sciences companies with a market capitalisation of over $50 billion. It's indicative of a burgeoning sector that is one of the key areas of economic growth in Australia.
Australia's drug discovery capabilities received a significant boost this year with the installation of state-of-the art, automated compound storage and screening facilities in Queensland.
At a time when technological advances focused on making life easier are being released on a daily basis, a Melbourne-based company, Sleeptite, is developing technology to make life better for older Australians.
For a patient, being able to access innovative therapies and medical tests through a clinical trial can sometimes be a matter of life and death.
Founded in 2008, the Medical Device Partnering Program (MDPP) started as an ideas incubator for the medtech-minded in South Australia. A decade later, the MTPConnect-supported program is expanding into other states and the big, bold ideas for new medical devices continue to flow.